We read that the FDA classifies Novo drugs as “available,” layoffs

Get up and smile everyone, another busy day is just around the corner. We can tell by the sudden presence of little ghouls and goblins walking by. No doubt they are looking for the big pumpkin. We wish them the best of luck because you never know what you will find on this elusive quest. Of course, this requires a cup full of stimulation, and to mark the occasion we open a new package of pecan pies. What awaits us right now, however, is our ever-growing to-do list. Does this sound familiar? Here are some interesting things. Have a nice day everyone. …

All doses of Novo Nordisk's blockbuster diabetes and obesity treatments are listed as available on the U.S. Food and Drug Administration's drug shortage list as of WednesdayThis raises the possibility that the drugs could soon be removed from the list entirely, a development that could impact prescription pharmacies and patients who rely on prescription medications, STAT reports. Semaglutide, the scientific name for Novo's GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different dosages listed as in short supply at different times. With all doses now listed as available, the FDA could soon delist the drug, depending on discussions with Novo about whether the company can adequately meet demand going forward.

The number of layoffs in the U.S. pharmaceutical industry fell last month, although job cuts remain well above what was seen at the same point in 2023. According to Challenger, Gray & Christmas, the outplacement and executive coaching company. A total of 424 jobs were cut in October, far fewer than the 3,073 jobs lost in September. This was also well below the 1,624 jobs the industry cut in October 2023. So far this year, pharmaceutical companies have cut a total of 12,751 jobs, surpassing the 10,025 jobs cut at the same time in 2023.